Salute e Benessere
IBA – TRANSPARENCY NOTIFICATION
IBA SA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on November 7 , 2025.
In its notification, IBA SA indicated that following an acquisition or disposal of securities or voting rights, the 2% threshold was crossed upwards by the company itself on May 30, 2025.
IBA Investments SRL is a subsidiary of Ion Beam Applications SA, which holds 100% of its shares. Ion Beam Applications SA is not a controlled entity.
This notification results from the share buyback carried out by Ion Beam Applications SA, which led to the upward crossing of the 2% statutory threshold set out in the company’s articles of association.
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
Elena De Landy
Paralegal: Corporate Affairs and Insurance
legal@iba-group.com
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti